On October 8, 2026, Illumina entered into definitive documentation to establish an unsecured commercial paper program with a maximum aggregate principal amount of $1.0 billion. The program allows the company to issue short-term notes maturing in up to 397 days for general corporate purposes. Three dealers were appointed to facilitate issuances, and no notes are currently outstanding under this facility. Illumina develops and sells DNA sequencing and array-based technologies.
